Pacific Biosciences Of California (PACB) Net Margin (2010 - 2026)

Pacific Biosciences Of California has reported Net Margin for 17 years, with the latest figure at 114.7% in Q2 2026.

• On a quarterly basis, Net Margin fell 926.0% year-over-year to 114.7% in Q2 2026; TTM through Jun 2026 was 82.49%, a 25468.0% increase from a year earlier, with the FY2025 full-year figure at 341.47%, down 14029.0% from the prior year.
• Net Margin was 114.7% for Q2 2026 at Pacific Biosciences Of California, down from 22.26% in the prior quarter.
• The five-year high for Net Margin was 6.04% in Q4 2024, with the low at 1146.81% in Q1 2025.
• Average Net Margin over 5 years is 224.14%, with a median of 149.36% recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Margin tumbled 94537 bps in 2025, then jumped 112455 bps in 2026.
• Over 5 years, Net Margin stood at 308.5% in 2022, then surged by 54 bps to 140.55% in 2023, then soared by 104 bps to 6.04% in 2024, then plunged by 1596 bps to 90.43% in 2025, then declined by 27 bps to 114.7% in 2026.
• The last three Net Margin figures came in at 114.7% (Q2 2026), 22.26% (Q1 2026), and 90.43% (Q4 2025), per Business Quant data.